Drevo Analytics
  • Home
  • Services
    • Competitive Intelligence
    • Market Research
    • Strategic Communications
  • About Us
  • Contact Us
  • Search

VaxInnate, a biotechnology company developing novel anti-flu vaccines, is selected to receive $21MM grant from New Jersey’s Technology Business Tax Certificate Transfer Program.

January 30, 2014/in News /by Competitive

Continue reading →

Tags: biotechnology, flu, infectious disease, non-dilutive financing, vaccine
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

Search

Tags

1st Pitch Life Sciences angiotensin II type 2 receptor antagonist autoimmune disease Best in Show Big Data biotechnology BoxGroup Brandon Capital Partners Canaan Partners Catalyst Health Ventures chronic pain Connecticut Innovations electronic medical records employee health benefits eye-tracking technology First Round flu GBS Venture Partners Google Ventures Harris & Harris Group infectious disease inflammation Lerer Ventures Mid-Atlantic Bio Angels New Atlantic Ventures New Leaf Venture Partners non-dilutive financing non-surgical device Novo A/S oncology Phase 2 prescription benefits protein degradation SaaS Series A Series B Series C Serious Change stress urinary incontinence Tribeca Venture Partners UniQuest Uniseed vaccine Vaizra Investments ventilator-associated pneumonia

Archive of news

  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • January 2014
  • December 2013
  • September 2013
© 2015 All rights reserved - Drevo Analytics, LLC
  • Accessibility
  • Credits
  • Privacy Policy
  • Terms of Use
Oculogica is named “Best in Show” at the Mid-Atlantic Bio Angels’... Connecticut-based Contine Corporation takes the win for Mid Atlantic Bio Angels’...
Scroll to top